Carbonic acid, (4-methylphenyl)methyl 4-nitrophenyl ester | 97557-59-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Carbonic acid, (4-methylphenyl)methyl 4-nitrophenyl ester
• 英文别名: (4-methylphenyl)methyl (4-nitrophenyl) carbonate
• CAS: 97557-59-0
• 化学式: C₁₅H₁₃NO₅
• 分子量: 287.272
• InChiKey: SQARJUVHPHSOSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  81.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  、 Carbonic acid, (4-methylphenyl)methyl 4-nitrophenyl ester 在 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以86%的产率得到
  参考文献：
  名称：

  Catalytic, selective, and stereocontrolled construction of C4 quaternary and homobenzylic dihydroisoquinolones by sp³ C–H benzylation

  摘要：

  一种选择性差异和催化的C(sp3)–C(sp3)偶联方案，其中β-氨基sp3 C–H键被sp3 C–苄基键取代，导致C4季碳和同苄基二氢异喹啉的形成。

  DOI：

  10.1039/c9ra10888b

文献信息

• METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID
  申请人：BHI Limited Partnership

  公开号：US20140220122A1

  公开（公告）日：2014-08-07

  The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease

  本发明涉及用于在受体内，尤其是人体内传递3-氨基-1-丙磺酸（3APS）的方法、化合物、组合物和载体。本发明包括可以在体内或体外生成或产生3APS的化合物。首选的化合物包括3APS的氨基酸前药，用于预防和治疗阿尔茨海默病等疾病。
• Acylpiperazines as Inhibitors of Transglutaminase and Their Use in Medicine
  申请人：ASTON UNIVERSITY

  公开号：US20150259310A1

  公开（公告）日：2015-09-17

  The present invention relates to novel compounds of Formula I capable of inhibiting tissue transglutaminase, and uses of the same in medicine. In particular, the invention provides compounds for use in the treatment of prevention of disease and conditions such as fibrosis (e.g. cystic fibrosis), scarring, neurodegenerative diseases (e.g. Alzheimer's disease, Huntington's disease and Parkinson's disease), autoimmune diseases (e.g. multiple sclerosis and coeliac disease), thrombosis, proliferative disorders (e.g. cancers), AIDS, psoriasis and inflammation (e.g. chronic inflammatory diseases).

  本发明涉及一种能够抑制组织转谷氨酰胺酶的新型化合物I，以及在医学上使用它们的方法。特别地，本发明提供了用于治疗和预防疾病和病况（如纤维化（例如囊性纤维化），瘢痕，神经退行性疾病（例如阿尔茨海默病，亨廷顿病和帕金森病），自身免疫性疾病（例如多发性硬化症和乳糜泻），血栓形成，增生性疾病（例如癌症），艾滋病，牛皮癣和炎症（例如慢性炎症性疾病））的化合物。
• N-substituted derivatives of 3R,4R-ethyl-[(1-methyl-1H-imidazol-5-yl)methyl]-2-pyrrolidinone
  申请人：ALLERGAN, INC.

  公开号：EP0429232A1

  公开（公告）日：1991-05-29

  The present invention relates to new carbonyl 3R,4R-­ethyl-[(1-methyl-1H-imidazol-5-yl)methyl]-2-pyrrolidinone derivatives carrying a carboxyester-type lipophilic moiety on the pyrrolidinone nitrogen. More particularly, the present invention concerns new N-substituted carbonyl-­3R,4R-ethyl-[(1-methyl-1H-imidazol-5-yl)methyl]-2-­pyrrolidinone derivatives of the formula (I): wherein R is an optionally substituted hydrocarbon group, and pharmaceutically acceptable acid addition salts thereof. The new compounds of the formula (I) are potent ocular hypotensives that are valuable antiglaucoma agents. They are also targeted for use in the treatment of so-called dry eye.

  本发明涉及新的羰基-3R,4R-乙基-[(1-甲基-1H-咪唑-5-基)甲基]-2-吡咯烷酮衍生物，其吡咯烷酮氮上带有羧酯型亲脂分子。 更具体地说，本发明涉及式（I）的新的 N-取代羰基-3R,4R-乙基-[(1-甲基-1H-咪唑-5-基)甲基]-2-吡咯烷酮衍生物：其中 R 是任选取代的烃基，以及它们的药学上可接受的酸加成盐。 式（I）的新化合物是有效的降眼压药，是有价值的抗青光眼药物。 它们还可用于治疗所谓的干眼症。
• AURISTATIN CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE
  申请人：Seattle Genetics, Inc.

  公开号：EP1545613B1

  公开（公告）日：2011-07-20
• SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS
  申请人：Caussil-Amblard Muriel

  公开号：US20120108748A1

  公开（公告）日：2012-05-03

  The present invention relates to the synthesis of depsipeptides on solid phase support. Said depsipeptides are then implicated in a solution phase O—N acyl shift enabling to obtain the corresponding peptide alcohols.